A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
NSCLC met mutatie
Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with
KRAS G12C mutation and known PD-L1 Tumor Proportion Score (TPS) score.
Unresectable or metastatic disease.
Not a candidate for definitive therapy (e.g., chemoradiation for locally advanced
Prior systemic treatment for locally advanced or metastatic NSCLC including
chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS
G12C mutation (e.g., AMG 510).
Radiation to the lung >30 Gy within 6 months prior to the first dose of study
Active brain metastases. Patients are eligible if brain metastases are adequately
treated and patients are neurologically stable (except for residual signs or symptoms
related to the central nervous system [CNS] treatment) for at least 2 weeks prior to
the first dose of study treatment without the use of corticosteroids or are on a stable or
decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie: